DexCom, Inc.

  • Market Cap: Mid Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US2521311074
USD
65.25
0.8 (1.24%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About DexCom, Inc. stock-summary
stock-summary
DexCom, Inc.
Pharmaceuticals & Biotechnology
Dexcom, Inc. (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company's products consist of DexCom G4 PLATINUM and DexCom G5 Mobile. The Company is commercializing its fifth generation CGM system. The Company's markets DexCom G4 PLATINUM under a Conformite Europeenne Marking (CE Mark), in the European Union, Australia, New Zealand and the countries in Asia and Latin America, and in the United States with approval from the United States Food and Drug Administration (FDA). The DexCom G4 PLATINUM with Share remote monitoring system uses a wireless connection between a patient's receiver and an application on the patient's iPhone, iPod touch, or iPad to transmit glucose information to applications on the mobile devices of designated recipients (followers).
Company Coordinates stock-summary
Company Details
6340 Sequence Dr , SAN DIEGO CA : 92121-4356
stock-summary
Tel: 1 858 2000200
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 186 Schemes (47.57%)

Foreign Institutions

Held by 485 Foreign Institutions (26.91%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Kevin Sayer
Chairman of the Board, President, Chief Executive Officer
Mr. Mark Foletta
Lead Independent Director
Mr. Steven Altman
Independent Director
Mr. Nicholas Augustinos
Independent Director
Mr. Richard Collins
Independent Director
Ms. Karen Dahut
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,157 Million
(Quarterly Results - Jun 2025)
Net Profit:
180 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 30,658 Million (Mid Cap)

stock-summary
P/E

64.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-0.18

stock-summary
Return on Equity

22.21%

stock-summary
Price to Book

11.91